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Objectives. We sought to assess the incidence and clinical
relevance of examination data to recurrent ischemia within an
international randomized trial.
Background. Ischemic symptoms commonly recur after throm-
bolysis for acute myocardial infarction.
Methods. Patients (n 5 40,848) were prospectively evaluated
for recurrent angina and transient electrocardiographic (ECG) or
hemodynamic changes. Five groups were developed: Group 1,
patients with no signs or symptoms of recurrent ischemia; Group
2, patients with angina only; Group 3, patients with angina and ST
segment changes; Group 4, patients with angina and hemody-
namic abnormalities; and Group 5, patients with angina, ST
segment changes and hemodynamic abnormalities. Baseline clin-
ical and outcome variables were compared among the five groups.
Results. Group 1 comprised 32,717 patients, and Groups 2 to 5
comprised 20% of patients (4,488 in Group 2; 3,021 in Group 3;
337 in Group 4; and 285 in Group 5). Patients with recurrent
ischemia were more often female, had more cardiovascular risk
factors and less often received intravenous heparin. Significantly
more extensive and more severe coronary disease, antianginal
treatment, angioplasty and coronary bypass surgery were ob-
served as a function of ischemic severity. The 30-day reinfarction
rate was 1.6% in Group 1, 6.5% in Group 2, 21.7% in Group 3,
13.1% in Group 4 and 36.5% in Group 5 (p < 0.0001); in contrast,
the 30-day mortality rate was significantly lower (p < 0.0001) in
Groups 1, 2 and 3 (6.6%, 5.4% and 7.7%, respectively) than in
Groups 4 and 5 (21.8% and 29.1%).
Conclusions. Postinfarction angina greatly increases the risk of
reinfarction, especially when accompanied by transient ECG
changes. However, mortality is markedly increased only in the
presence of concomitant hemodynamic abnormalities.
(J Am Coll Cardiol 1998;31:94–102)
©1998 by the American College of Cardiology
In-hospital recurrent ischemia after acute myocardial infarc-
tion (MI) has been recognized for years as a marker of both
death and reinfarction (1–7). In practice, most patients do not
undergo special monitoring to detect ischemia; only when
ischemic symptoms occur are symptom assessment, physical
examination and electrocardiography (ECG) performed. The
relevance of the various clinical and ECG findings during an
episode of postinfarction angina remains to be elucidated. In
addition, although the outcome of patients presenting with
myocardial ischemia after MI may not be changed by previous
thrombolysis (8–13), no large study has prospectively assessed
the incidence and clinical implications of symptoms compatible
with recurrent ischemia in the thrombolytic era. We analyzed,
as part of the Global Utilization of Streptokinase and t-PA
[tissue-plasminogen activator] for Occluded Coronary Arteries
(GUSTO-I) trial, the incidence of the examination data col-
lected during recurrent ischemia and evaluated their relation
to clinical outcomes.
Methods
Study patients. The GUSTO-I trial has been described in
detail (14). In brief, eligible patients were randomized to one
of four thrombolytic strategies if they presented within 6 h of
the onset of chest pain and met ECG criteria of acute MI
($0.1-mV ST segment elevation in two or more limb leads or
$0.2 mV in two or more contiguous precordial leads). Patients
were excluded only for bleeding or allergic risk factors.
All patients received chewable aspirin on entry and daily
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thereafter. Patients with no contraindication were to receive
intravenous atenolol on entry, followed by daily oral therapy.
All other medications were prescribed at the discretion of the
attending physician.
Data collection and study design. Baseline clinical vari-
ables were collected for all patients with standard data collec-
tion forms. Quality control was checked at data entry, and
missing or questionable answers were queried. A sample of
12% of the forms was audited by comparing data on the form
with the hospital medical record.
Investigators were to record the date and time of the first
episode of recurrent ischemia, defined as the first appear-
ance of symptoms (such as chest, arm or jaw pain; nausea;
and others) or signs (ECG changes or new sustained
hypotension [systolic blood pressure ,90 mm Hg, or
.30 mm Hg less than the previous measure, for .1 h,
despite fluid administration], pulmonary edema or a mur-
mur thought by the clinician to represent ischemia). When
such symptoms or signs occurred, the following variables
were recorded: ST segment deviation from baseline, pres-
ence of pulmonary rales, third sound gallop and hypoten-
sion. Data on recurrent ischemia were lacking for 173 of the
41,021 patients in GUSTO-I.
The patient was then categorized into one of five groups.
Group 1 included patients with no signs or symptoms (as just
listed) of recurrent ischemia; Group 2, patients with angina but
without documented ST segment changes or hemodynamic
abnormalities; Group 3, patients with angina and ST segment
changes but without hemodynamic abnormalities; Group 4,
patients with angina and hemodynamic abnormalities but
without documented ST segment changes; and Group 5,
patients with angina, ST segment changes and hemodynamic
abnormalities. These categories are in keeping with the rec-
ommendations of the Agency for Health Care Policy and
Research (AHCPR) (15) for the management of patients with
unstable angina, which emphasize the importance of risk
stratification based on clinical presentation, ECG findings and
physical examination data.
End points and definitions. Prospectively defined end
points were 30-day mortality, reinfarction, cardiogenic shock,
use of angioplasty or bypass surgery and length of hospital stay.
Reinfarction was diagnosed by the presence of at least two of
the following four criteria: 1) ischemic symptoms lasting
.15 min occurring after resolution of symptoms of the index
infarction; 2) occurrence of new ST-T wave changes or new Q
waves; 3) reelevation in cardiac enzymes above the normal
upper limit (or by another 20% if already above the normal
upper limit); or 4) angiographic reocclusion of an infarct-
related artery previously patent. Definition of shock included
systolic blood pressure ,90 mm Hg for .1 h that was
unresponsive to fluid administration, considered secondary to
cardiac dysfunction and associated with signs of hypoperfusion
(cool, clammy skin, oliguria or altered sensorium) or cardiac
index #2.2 liters/min per m2; if the patient presented with
cardiogenic shock at enrollment, that episode did not count for
this end point.
Statistical analysis. Baseline characteristics and clinical
outcomes are presented as percentages for binary variables
and medians with 25th and 75th percentiles for continuous
characteristics. Statistical testing was confined to analyses of
whether a significant association was present for each charac-
teristic such that a greater proportion of patients with the
outcome of interest was found in groups with greater findings
of ischemia than in groups with lesser findings of ischemia.
Because of the multiple possible comparisons, specific testing
of the significance of differences between individual groups was
avoided. For the GUSTO-I trial as a whole, when comparing
patients with and without recurrent ischemia, for example, any
differences .1% in baseline characteristics or outcomes would
have a nominal p value , 0.001.
Selected baseline characteristics and clinical outcomes were
compared among the five groups by chi-square tests for
discrete variables and by nonparametric analysis of variance
(Kruskal-Wallis) for continuous variables. Kaplan-Meier esti-
mates were calculated for 30-day and 1-year survival and time
to reinfarction for each recurrent ischemia category.
Results
A total of 40,848 patients had data available for review.
Symptoms of possible recurrent ischemia occurred in 8,131
(20%) of the study patients (Groups 2 to 5, Table 1). Patients
with recurrent ischemia were more likely to be female, hyper-
tensive and hypercholesterolemic, and they more often had
prior angina and prior MI than those without recurrent
ischemia. In general, baseline factors associated with mortality
were more prevalent in patients who later had more severe
clinical manifestations of recurrent ischemia.
No major differences were found among the five groups
with respect to assigned thrombolytic agent and time to
thrombolytic treatment (Table 2). However, patients with
recurrent ischemic symptoms received intravenous heparin less
often, and for a shorter duration, than those without symp-
toms. Activated partial thromboplastin time (aPTT) values at
24 h were slightly but statistically significantly higher in pa-
tients with recurrent ischemia.
Although beta-adrenergic blocking agents were given
equally among the five groups, patients with recurrent ischemia
received nitrates, calcium channel antagonists, digitalis and
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AHCPR 5 Agency for Health Care Policy and Research
aPTT 5 activated partial thromboplastin time
CK 5 creatine kinase
ECG 5 electrocardiography, electrocardiographic
GUSTO-I 5 Global Utilization of Streptokinase and t-PA
for Occluded Coronary Arteries
MI 5 myocardial infarction
TIMI 5 Thrombolysis in Myocardial Infarction
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angiotensin-converting enzyme (ACE) inhibitors more often
than those without symptoms (Table 2). The use of diagnostic
and therapeutic procedures, including angioplasty and coro-
nary artery bypass surgery, increased as a function of ST
segment changes and hemodynamic impairment.
Angiography (Table 3) was performed more often in pa-
tients with symptoms of recurrent ischemia, and it was more
often done on an emergency basis in these groups. Reperfu-
sion of the infarct-related coronary artery (Thrombolysis in
Myocardial Infarction [TIMI] grade 3 blood flow) was more
prevalent in patients without recurrent symptoms of ischemia,
whereas more severe stenoses, triple-vessel disease and lower
ejection fractions were observed in the recurrent ischemia
groups, with a greater frequency of markers of more severe
disease present in patients with more severe manifestations of
ischemia.
Clinical events are listed in Table 4. The median time to
onset of recurrent ischemia was 1.5 days. Again, worse out-
comes and longer hospital stays paralleled the severity of
recurrent ischemia. In patients who had a reinfarction, the
reinfarction tended to occur simultaneously with recurrent
ischemia. Among patients who died, death tended to occur
shortly after the recurrent ischemia when the recurrent isch-
emic event was accompanied by hemodynamic abnormalities,
whereas death most often occurred several days later in
patients with recurrent ischemia without evidence of hemody-
namic distress. Mortality at 30 days did not appear to increase
in patients whose angina was not accompanied by hemody-
namic impairment (Groups 2 and 3), but it was dramatically
higher in the presence of signs of heart failure (Groups 4 and
5). This is well illustrated in Figure 1A, where the Kaplan-
Meier survival curves for Groups 1, 2 and 3 appear similar,
with mortality rates of 6.6%, 5.4%, and 7.7%, respectively, at
30 days, and are significantly lower than those of Groups 4 and
5 (21.8% and 29.1%, respectively). Figure 1B shows that this
pattern was maintained at 1 year. In contrast, the rate of
reinfarction, increased with the mere presence of angina and
was even higher with concomitant ECG changes, hemody-
namic impairment, or both. The corresponding Kaplan-Meier
curves are depicted in Figure 2.
Table 1. Baseline Characteristics by Recurrent Angina Category
Group 1
(n 5 32,717)
Group 2
(n 5 4,488)
Group 3
(n 5 3,021)
Group 4
(n 5 337)
Group 5
(n 5 285)
Age (yr) 61.3 (51.9, 69.7) 61.5 (52.0, 69.8) 63.0 (54.1, 70.6) 65.4 (56.3, 71.8) 64.9 (55.7, 71.4)
Male gender 24,884 (76.1%) 3,117 (69.5%) 2,108 (69.8%) 221 (65.6%) 230 (80.7%)
Weight (kg) 78.2 (70, 88.6) 79 (69, 89) 77 (68, 87) 76 (67, 86) 76 (66, 85)
Height (cm) 172 (165, 178) 172 (164, 178) 170 (164, 178) 170 (163, 177) 170 (165, 178)
History of hypertension 12,058 (37.0%) 1,897 (42.3%) 1,257 (41.6%) 132 (39.2%) 151 (53.0%)
History of diabetes 4,665 (14.3%) 683 (15.2%) 521 (17.2%) 59 (17.5%) 59 (20.7%)
Current smoking 14,433 (44.1%) 1,722 (38.4%) 1,058 (35.0%) 115 (34.6%) 128 (44.9%)
Former smoking 22,606 (69.1%) 3,121 (69.5%) 1,979 (65.5%) 214 (65.6%) 220 (77.2%)
History of hypercholesterolemia 10,551 (32.2%) 1,676 (37.3%) 1,071 (35.5%) 128 (39.3%) 126 (44.2%)
Family history of CAD 12,985 (39.7%) 2,011 (44.8%) 1,236 (40.9%) 140 (43.9%) 148 (51.9%)
Prior infarction 5,182 (15.8%) 777 (17.3%) 593 (19.6%) 61 (18.1%) 64 (22.5%)
Prior angina 11,272 (34.5%) 2,041 (45.5%) 1,410 (46.7%) 139 (41.5%) 139 (48.8%)
Prior coronary bypass surgery 1,316 (4.0%) 250 (5.6%) 171 (5.7%) 20 (5.9%) 17 (6.0%)
Prior angioplasty 1,245 (3.8%) 208 (4.6%) 158 (5.2%) 12 (3.6%) 14 (4.9%)
Heart rate (beats/min) 74 (63, 86) 72 (62, 84) 72 (62, 84) 74 (62, 88) 74 (60, 88)
Systolic blood pressure (mm Hg) 130 (112, 144) 130 (113, 145) 129 (113, 143) 124 (108, 140) 124 (108, 140)
Diastolic blood pressure (mm Hg) 80 (70, 90) 80 (70, 90) 80 (70, 89) 75 (67, 85) 76 (67, 88)
Killip class
I 27,883 (85.6%) 3,723 (83.0%) 2,550 (84.7%) 271 (80.7%) 281 (98.6%)
II 3,982 (12.2%) 619 (13.8%) 403 (13.4%) 53 (15.8%) 52 (18.2%)
III 426 (1.3%) 53 (1.2%) 46 (1.5%) 9 (2.7%) 10 (3.5%)
IV 273 (0.8%) 11 (0.3%) 13 (0.4%) 3 (0.9%) 8 (2.8%)
Location of infarction
Anterior 12,650 (38.7%) 1,745 (38.9%) 1,207 (40.1%) 150 (44.5%) 141 (49.5%)
Inferior 18,826 (57.5%) 2,520 (56.1%) 1,711 (56.8%) 177 (52.5%) 202 (70.9%)
Other 1,094 (3.3%) 143 (3.2%) 94 (3.1%) 10 (3.0%) 7 (2.5%)
Peak CK (IU/liter) (n 5 30,933) (n 5 4,320) (n 5 2,912) (n 5 330) (n 5 330)
Median 1,409 (643, 2,642) 1,446 (684, 2,669) 1,350 (613, 2,642) 2,019 (995, 3,354) 2,063 (883, 3,686)
Peak CK-MB (IU/liter) (n 5 13,124) (n 5 1,605) (n 5 1,286) (n 5 133) (n 5 144)
Median 120 (56, 234) 122 (57, 228) 119 (55, 246) 149 (78, 272) 169 (89, 338)
Data presented are median (25th, 75th percentiles) or number (%) of patient group. CAD 5 coronary artery disease; CK 5 creatine kinase; Group 1 5
patients without signs or symptoms of recurrent ischemia; Group 2 5 patients with angina only; Group 3 5 patients with angina and ST segment changes; Group
4 5 patients with angina and hemodynamic abnormalities; Group 5 5 patients with angina, ST segment changes and hemodynamic abnormalities.
96 BETRIU ET AL. JACC Vol. 31, No. 1
RECURRENT ISCHEMIA AFTER THROMBOLYSIS January 1998:94–102
Discussion
The reported incidence of recurrent ischemia after MI
varies considerably, ranging from 6% to 50% in representative
series of patients who did not receive thrombolytic treatment
(1–6,9–12). The large Multicenter Postinfarction Research
Trial (16) and the Perth Coronary Registry (17) reported an
incidence of 33% and 38%, respectively. The wide variation of
these figures might be explained by differences in both the
clinical characteristics of the study patients and the diagnostic
criteria used. For example, the lowest incidence corresponds to
a study limited to patients with Q wave MI (5), whereas the
highest relates to patients presenting with non-Q wave MI
(18,19). Similarly, some studies have considered recurrent
ischemia after a first MI only (7), whereas most series have
included recurrence after any MI. In addition, the number of
episodes of chest pain required to qualify (20,21), the severity
of these episodes (22), the need for concurrent ECG changes
(1,2,5,23) and the time window chosen (21) are not uniform
among the different studies.
Another critical issue in understanding the incidence of
recurrent ischemia is the technology used to define its pres-
ence. In a recent study of 406 postinfarction patients (24),
many of whom did not receive thrombolytic therapy, 23% had
recurrent angina and 23% had ischemia diagnosed within 48 h
of admission by continuous ambulatory ECG monitoring.
Given that many asymptomatic episodes of ambulatory isch-
emia occurred and that monitoring continued for only 48 h,
continuous monitoring for a longer period would more likely
have found greater evidence of ischemia. Similarly, in a subset
of the GUSTO-I patients, Langer and colleagues (25) found a
high incidence of recurrent ischemia in the first 48 h.
Patients successfully treated by thrombolytic therapy may
be at increased risk for postinfarction angina (8,26), although
studies have produced conflicting results (9,12). In the study by
Campolo and colleagues (4), in which many patients under-
went thrombolysis, the incidence of postinfarction angina was
26%. Silva and colleagues (27) found early recurrent ischemia,
defined by spontaneous chest pain and ST-T wave changes, to
be present in 35 (8%) of 453 low risk patients after the first
24 h of an uncomplicated course after thrombolysis. A recent
review of the Thrombolysis and Angioplasty in Myocardial
Infarction (TAMI) series (13) found an 18.3% incidence of
recurrent ischemia, defined by symptoms and associated ECG
changes. Stone and colleagues (28) noted a higher incidence,
Table 2. Thrombolytic Therapy Assignment and In-Hospital Management by Recurrent
Angina Category
Group 1
(n 5 32,717)
Group 2
(n 5 4,488)
Group 3
(n 5 3,021)
Group 4
(n 5 337)
Group 5
(n 5 285)
Time to treatment (h) 2.8 (2, 3.9) 2.8 (2, 3.9) 2.7 (1.9, 3.8) 2.9 (2.1, 4.2) 2.8 (1.9, 3.9)
Thrombolytic therapy
Accelerated t-PA 8,318 (25.4%) 1,118 (24.9%) 764 (25.2%) 78 (23.2%) 80 (28.1%)
SK 1 iv heparin 8,285 (25.3%) 1,114 (24.8%) 803 (26.6%) 91 (27.0%) 83 (29.1%)
SK 1 sc heparin 7,789 (23.8%) 1,086 (24.2%) 738 (24.4%) 88 (26.1%) 94 (33.0%)
Combination therapy 8,325 (25.4%) 1,105 (24.6%) 714 (23.6%) 80 (23.7%) 95 (33.3%)
sc heparin not given 22,822 (69.8%) 2,972 (66.2%) 2,110 (69.8%) 229 (70.9%) 251 (88.1%)
Heparin not given 5,785 (17.7%) 512 (11.4%) 247 (8.2%) 29 (8.9%) 29 (10.2%)
iv heparin for $48 h 16,877 (51.6%) 2,116 (47.1%) 1,431 (47.4%) 147 (48.7%) 121 (42.4%)
Heparin given per protocol 23,978 (73.3%) 2,929 (65.3%) 1,925 (63.7%) 205 (61.2%) 203 (71.2%)
Heparin duration (h) (n 5 26,236) (n 5 3766) (n 5 2681) (n 5 302) (n 5 309)
Median 48 (46, 48) 48 (44, 48) 48 (40, 48) 47 (24, 48) 46 (24, 48)
aPTT at 24 h (s) (n 5 22,130) (n 5 2,826) (n 5 2,030) (n 5 194) (n 5 201)
Median 60 (44, 85) 61 (46, 86) 62 (46, 95) 60 (47, 87) 64 (47, 100)
Beta-blocker—iv 14,162 (43.3%) 2,239 (49.9%) 1,412 (46.7%) 181 (53.7%) 153 (53.7%)
Beta-blocker—oral 22,852 (69.8%) 3,416 (76.1%) 2,313 (76.6%) 227 (67.6%) 238 (83.5%)
Calcium channel blocker 8,831 (27.0%) 1,842 (41.0%) 1,496 (49.5%) 132 (39.4%) 125 (43.9%)
Digitalis 3,957 (12.1%) 741 (16.5%) 596 (19.7%) 89 (26.7%) 93 (32.6%)
Nitrates—oral 19,525 (59.7%) 3,578 (79.7%) 2,319 (76.8%) 260 (78.8%) 238 (83.5%)
Nitrates—iv 23,599 (72.1%) 3,731 (83.1%) 2,676 (88.6%) 294 (87.5%) 272 (95.4%)
ACE inhibitors 6,704 (20.5%) 1,102 (24.6%) 796 (26.3%) 120 (36.8%) 107 (37.5%)
Swan-Ganz catheter 3,363 (10.3%) 735 (16.4%) 671 (22.2%) 130 (38.6%) 140 (49.1%)
Cardioversion/defibrillation 2,916 (8.9%) 382 (8.5%) 365 (12.1%) 60 (17.9%) 96 (33.7%)
Pacemaker 1,981 (6.1%) 391 (8.7%) 348 (11.5%) 57 (17.0%) 80 (28.1%)
Intraaortic balloon pump 834 (2.5%) 221 (4.9%) 278 (9.2%) 54 (16.1%) 85 (29.8%)
Ventilator 3,209 (9.8%) 619 (13.8%) 592 (19.6%) 106 (31.6%) 120 (42.1%)
Angioplasty 5,944 (18.2%) 1,400 (31.2%) 1,306 (43.2%) 115 (34.3%) 153 (53.7%)
Bypass surgery 2,224 (6.8%) 596 (13.3%) 563 (18.6%) 59 (17.6%) 72 (25.3%)
Data presented are median (25th, 75th percentiles) or number (%) of patient group. ACE 5 angiotensin-converting
enzyme; aPTT 5 activated partial thromboplastin time; iv 5 intravenous; sc 5 subcutaneous; SK 5 streptokinase;
t-PA 5 tissue-type plasminogen activator. Groups as defined in Table 1.
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28% (56 of 200 patients treated with alteplase), despite the use
of stringent criteria to define recurrent ischemia: chest pain for
.20 min and ECG changes or new onset pulmonary edema,
holosystolic murmur or hypotension. The incidence in the
present study (20% [8% when the definition includes only
ECG changes]) does not support the hypothesis that recurrent
ischemia is more common in patients who undergo thrombol-
ysis, at least not when heparin is given (as in GUSTO-I).
However, the protocol called for the use of intravenous and
oral beta-blockers (29), which might well have prevented
recurrent ischemia. In contrast, the thrombolytic agent given
did not play a significant role in the occurrence of postinfarc-
tion angina.
Clinical and angiographic profiles of patients with recur-
rent ischemia. Age, preinfarction angina, lower creatine ki-
nase (CK) values, and non-Q wave MI have been shown to be
independent predictors of postinfarction ischemia (1,7,30–34).
In particular, the importance of antecedent angina as a pre-
dictor of worse outcomes after thrombolysis has recently been
stressed (35). In keeping with these data are our findings of an
association between advanced age and a higher prevalence of
prior angina in the recurrent ischemia groups. In contrast, we
did not observe lower CK-MB values in these subsets; indeed,
peak total CK and peak CK-MB values were higher in the
presence of hemodynamic impairment. This is probably to be
expected, however, because our study did not exclusively enroll
patients with non-Q wave MI, who presumably have less
extensive tissue necrosis and more ischemic, but not infarcted,
myocardium (20,36,37).
From the angiographic standpoint, recurrent ischemia has
been related to the extent and severity of coronary artery
disease (1–3,7,31,38–40). Although these data have generally
been derived from smaller series, they do not differ from our
findings. Along with the higher prevalence of triple-vessel
disease and more severe stenoses, we observed lower rates of
TIMI grade 3 blood flow, always as a function of the severity of
recurrent ischemia. In judging these results, however, one
should consider that clinical indications led to appropriately
different rates of angiography among the study groups (51% in
patients without recurrent ischemia to 80% in those with
ischemia and ECG changes), for both elective (78% in Group
1 vs. 41% in Group 5) and emergency (10% vs. 53%) catheter-
izations. Indeed, the absence of angiography in 20% of patients
with recurrent ischemia raises questions about whether closer
adherence to guidelines for angiography is needed. In a
detailed analysis of the use of angiography in GUSTO-I, Pilote
and colleagues (41) showed that age is the primary criterion for
angiography, with recurrent ischemia a distant second.
Given the low sensitivity and specificity of coronary angiog-
raphy to detect thrombus (42,43), its presence was not assessed
systematically in this nonmechanistic study. Recently, coronary
angioscopy performed in patients with recent MI identified
coronary thrombus in all 17 patients with postinfarction angina
but in only 5 of 34 without angina (44).
Table 3. Angiographic Characteristics by Recurrent Angina Category
Group 1
(n 5 32,717)
Group 2
(n 5 4,488)
Group 3
(n 5 3,021)
Group 4
(n 5 337)
Group 5
(n 5 285)
Angiography performed 16,692 (51.0%) 3,033 (67.6%) 2,423 (80.2%) 231 (68.8%) 259 (90.1%)
Infarct-related vessel
LAD 5,986 (36.3%) 1,102 (36.6%) 891 (37.0%) 88 (38.4%) 90 (35.0%)
LCx 1,995 (12.1%) 349 (11.6%) 230 (9.6%) 23 (10.0%) 25 (9.7%)
RCA 7,414 (44.9%) 1,392 (46.2%) 1,120 (46.5%) 104 (45.4%) 131 (51.0%)
LMCA 68 (0.4%) 12 (0.4%) 7 (0.3%) 1 (0.4%) 4 (1.6%)
Bypass graft 247 (1.5%) 70 (2.3%) 61 (2.5%) 2 (0.9%) 3 (1.2%)
Catheterization type
Elective 12,980 (77.8%) 2,081 (68.7%) 1,277 (52.8%) 117 (50.9%) 106 (40.8%)
Emergency 1,589 (9.5%) 741 (24.5%) 953 (39.4%) 106 (46.1%) 137 (52.7%)
Protocol-driven 2,100 (12.6%) 206 (6.8%) 190 (7.9%) 7 (3.0%) 17 (6.5%)
TIMI flow grade
1 1,014 (10.2%) 189 (11.5%) 189 (12.7%) 21 (17.7%) 22 (13.2%)
2 2,146 (21.7%) 392 (23.8%) 353 (23.7%) 26 (21.9%) 31 (18.6%)
3 5,025 (50.7%) 752 (45.6%) 584 (39.3%) 40 (33.6%) 62 (37.1%)
Percent stenosis (n 5 15,813) (n 5 2928) (n 5 2311) (n 5 222) (n 5 252)
Median 90 (80, 99) 90 (80, 99) 95 (90, 99) 95 (90, 99) 95 (90, 100)
No. of diseased vessels
0 1,410 (10.1%) 149 (5.8%) 79 (3.9%) 3 (1.6%) 5 (2.4%)
1 6,511 (46.5%) 1,158 (44.9%) 889 (43.9%) 81 (43.8%) 102 (48.3%)
2 3,798 (27.1%) 779 (30.2%) 579 (28.6%) 58 (31.4%) 53 (25.1%)
3 2,283 (16.3%) 493 (19.1%) 478 (23.6%) 43 (23.2%) 51 (24.2%)
LV ejection fraction (%) (n 5 12,015) (n 5 2,046) (n 5 1,531) (n 5 142) (n 5 166)
Median 52 (44, 60) 50 (42, 60) 50 (40, 60) 50 (40, 58) 49.5 (37, 56)
Data presented are median (25th, 75th percentiles) or number (%) of patient group. LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; LMCA 5 left main coronary artery; LV 5 left ventricular; RCA 5
right coronary artery; TIMI 5 Thrombolysis in Myocardial Infarction. Groups as defined in Table 1.
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Patients with recurrent ischemic symptoms received intra-
venous heparin less often and for a shorter time, suggesting
that intracoronary thrombus, platelet aggregation, or both,
may play a role in the pathophysiology of postinfarction
angina. However, the heparin data are confounded by uncer-
tainty about why the heparin may have been discontinued early
in each case. In some cases recurrent ischemia may have
occurred after heparin was discontinued early because of
bleeding or thrombocytopenia. Randomized trials of heparin
therapy have shown a reduction in MI (45) and recurrent
ischemia (46), although the duration of this benefit is contro-
versial (47).
Clinical outcomes: the continuum of risk. Most studies
have shown a definite prognostic value of early postinfarction
angina with regard to mortality (from 17% to 56% at 1 year)
and reinfarction (10% to 33%) (1–7,18,48). Again, differences
in the study patients and the inclusion criteria may account for
the variation. When accompanying ECG changes are not
required to qualify for the study, differences in mortality
between patients with and without early postinfarction angina
may vanish (48,49). Despite that background, however, little
attention has been paid to the comparison of outcomes of
patients with postinfarction angina who present with or with-
out transient ischemic ECG changes. In the study by Bosch and
colleagues (50), which specifically addressed this issue, the
probability of survival or survival without reinfarction of
patients with angina but no ST segment changes approached
that of patients without postinfarction angina and was signifi-
cantly better than that of patients whose angina was accompa-
nied by ECG changes. Nevertheless, the use of revasculariza-
tion procedures was higher in the subset of patients with
angina alone than in patients with no recurrent chest pain, and
the investigators concluded that patients with angina and no
ECG changes constitute—in terms of risk—an intermediate
group between the patients without angina and those with
angina and transient ECG changes. Furthermore, in the
present study some ECGs were obtained promptly with no
evidence of a change, whereas in other cases they were simply
not obtained; thus, Group 2 may contain two populations with
different prognoses.
Recently, the AHCPR (15) published clinical practice
guidelines for the treatment of unstable angina. Three catego-
ries of risk were defined, in which patients with prolonged
angina, those with dynamic ST segment changes and those with
Table 4. Outcomes and Clinical Events* by Recurrent Angina Category
Group 1
(n 5 32,717)
Group 2
(n 5 4,488)
Group 3
(n 5 3,021)
Group 4
(n 5 337)
Group 5
(n 5 285)
Time to recurrent ischemia (days) — 1.6 (0.6, 4.0) 2.7 (1.1, 5.1) 1.4 (0.6, 3.8) 1.5 (0.4, 4.0)
In-hospital mortality 2,069 (6.3%) 227 (5.1%) 220 (7.3%) 71 (21.1%) 83 (29.1%)
Time from recurrent ischemia to death (days) — 2.7 (8.0, 0.8) 2.0 (0.6, 6.1) 1.0 (0.1, 3.5) 0.3 (0.1, 1.3)
30-day mortality 2,174 (6.6%) 242 (5.4%) 232 (7.7%) 73 (21.8%) 83 (29.1%)
Excluding early (,12 h) deaths 1,276 (3.9%) 202 (4.5%) 202 (6.7%) (18.1%) 58 (20.4%)
1-year mortality rate† (9.4%) (8.6%) (10.6%) (26.5%) (27.9%)
Stroke 460 (1.4%) 62 (1.4%) 59 (2.0%) 2 (0.6%) 7 (2.5%)
Death or hemorrhagic stroke 2,259 (6.9%) 250 (5.6%) 245 (8.1%) 74 (22.0%) 84 (29.5%)
Death or nonfatal, disabling stroke 2,315 (7.1%) 276 (6.1%) 259 (8.6%) 74 (22.0%) 87 (30.5%)
Reinfarction 525 (1.6%) 293 (6.5%) 656 (21.7%) 44 (13.1%) 104 (36.5%)
Time from recurrent ischemia to reinfarction (days) — 0.1 (0, 2.1) 0 (0, 0) 0 (0, 0.7) 0 (0, 0)
Sustained hypotension 3,574 (10.9%) 509 (11.3%) 442 (14.6%) 143 (42.6%) 184 (64.6%)
Cardiogenic shock 1,774 (5.4%) 223 (5.0%) 227 (7.5%) 96 (28.6%) 107 (37.5%)
CHF or pulmonary edema 4,577 (14.0%) 966 (21.5%) 748 (24.8%) 158 (47.2%) 152 (53.3%)
Acute mitral regurgitation 371 (1.1%) 79 (1.8%) 73 (2.4%) 26 (7.8%) 21 (7.4%)
Ventricular septal defect 146 (0.5%) 22 (0.5%) 14 (0.5%) 4 (1.2%) 6 (2.1%)
Tamponade 250 (0.8%) 30 (0.7%) 17 (0.6%) 4 (1.2%) 8 (2.8%)
Worst Killip class
I 22,242 (68.0%) 2,564 (57.1%) 1,623 (53.7%) 107 (32.0%) 130 (45.6%)
II 7,636 (23.3%) 1,441 (32.1%) 975 (32.3%) 120 (35.9%) 95 (33.3%)
III 1,277 (3.9%) 236 (5.3%) 207 (6.9%) 42 (12.6%) 39 (13.7%)
IV 1,352 (4.1%) 163 (3.6%) 196 (6.5%) 66 (19.5%) 87 (30.5%)
Atrioventricular block 2,557 (7.8%) 345 (7.7%) 323 (10.7%) 63 (18.8%) 87 (30.5%)
Sustained ventricular tachycardia 1,908 (5.8%) 279 (6.2%) 201 (6.7%) 45 (13.4%) 80 (28.1%)
Ventricular fibrillation 2,113 (6.5%) 251 (5.6%) 243 (8.0%) 55 (16.4%) 66 (23.2%)
Asystole 1,799 (5.5%) 204 (4.5%) 188 (6.2%) 60 (17.9%) 69 (24.2%)
Atrial fibrillation/flutter 2,747 (8.4%) 520 (11.6%) 429 (14.2%) 55 (16.4%) 70 (24.6%)
Moderate or severe bleeding 3,596 (11.0%) 640 (14.3%) 692 (22.9%) 89 (26.4%) 124 (43.5%)
Fever, chills, allergic reaction 1,409 (4.3%) 220 (4.9%) 159 (5.3%) 16 (4.8%) 18 (6.3%)
Hospital stay (days) 9 (7, 12) 10 (7, 14) 11 (8, 17) 11 (7, 15) 11 (6, 17)
*All outcomes and events are in-hospital data except 30-day and 1-year mortality. †Kaplan-Meier estimates. Data presented are median (25th, 75th percentiles)
or number (%) of patient group. CHF 5 congestive heart failure. Groups as defined in Table 1.
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any evidence of acute heart failure were classified in the high
risk group. This classification, predominantly describing unsta-
ble angina in the absence of a recent MI, recognizes the
additional prognostic value of transient ECG changes. How-
ever, few data have been published on the role of ischemic
symptoms accompanied by hemodynamic deterioration. Our
observations show that with a simple evaluation, including
symptom assessment, physical examination and ECG, a con-
tinuum of risk can be established for patients with recurrent
angina after thrombolysis for acute MI. Furthermore, the risk
gradient was not uniform across the five groups; some signs
and symptoms were associated with a very high risk. Thus,
although mortality increased substantially only in the presence
of hemodynamic impairment, the risk of reinfarction rose with
angina alone (and rose still further with accompanying ECG
changes).
Limitations of the study. The present series illustrates that
.50% of patients with recurrent ischemia do not show accom-
panying ECG changes. This finding implies that in the corre-
sponding patient subset (Group 2), the diagnosis was made on
clinical grounds. Other than the ECG, no procedures such as
echocardiography or scintigraphy were routinely carried out to
confirm ischemia. Nevertheless, angina pectoris remains a
clinical diagnosis, based on the characteristics of the symp-
toms. Although particular attention was paid to exclusion of all
other causes of nonischemic pain, identification of the exact
nature of an episode of chest discomfort is often not easy; thus,
the possibility of an incorrect diagnosis in individual patients
cannot be ruled out. However, the results of the study remain
relevant because the occurrence of chest pain (regardless of
etiology) places the patient in a higher risk category.
Despite the size of the study group, the relative prognostic
Figure 1. Kaplan-Meier curves of 30-day
(A) and 1-year (B) survival, by recurrent
angina category. Mortality was significantly
(p , 0.0001) lower at 30 days for Groups 1
(light solid line), 2 (heavy solid line) and 3
(line with circles) than for Groups 4 (short
dashes) and 5 (long dashes), and this pat-
tern persisted at 1 year.
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values of the various components of the hemodynamic abnor-
malities (pulmonary rales, third sound gallop and hypotension)
were not separately analyzed, given the small number of
patients included in Group 4.
Finally, the prognostic implications of silent ischemia were
not elucidated in our series. Although ambulatory ECG may
provide prognostic information beyond that from standard
clinical variables (24), continuous recording was not performed
in this large study; thus, the category of patients with ECG
changes but no angina could not be evaluated.
Clinical implications. Symptoms of recurrent ischemia
after MI remain frequent in the thrombolytic era, occurring
in one of five patients despite the liberal use of heparin,
beta-blockers and aspirin. Patients presenting with recur-
rent ischemia fall along a continuum of risk for negative
outcomes as a function of ECG changes and hemodynamic
burden. Angina alone does not seem to increase the short-
or long-term risk of death, but it constitutes a marker of
reinfarction and use of revascularization procedures. Al-
though the risk of reinfarction is further increased by
concurrent ECG changes, our findings reinforce the value of
careful clinical evaluation. Death and cardiogenic shock are
increased when hemodynamic abnormalities are present.
Emphasis should be placed on prompt ECG and physical
examination when symptomatic ischemia occurs, and appro-
priate management strategies should be based on the sever-
ity of risk as assessed during the period of acute ischemia, as
well as on the coronary anatomy, left ventricular function
and other associated conditions.
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